These pages are designed to help you understand MPNs.
MPN Alliance Australia Newsletter
Ruxolitinib available for some PV patients?
The Pharmaceutical Benefits Advisory Committee is open for comments from patients about the possible inclusion of ruxolitinib (Jakavi®) onto the PBS for some PV patients resistant or intolerant to Hydroxyurea.
If you have PV, you may wish to make a submission. It's simple - see HERE for how!